Cargando…

Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data

INTRODUCTION: The safety profile of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA) is well established. TCZ was approved to treat giant cell arteritis (GCA) in 2017 in the USA and Europe, and its safety profile in patients with GCA continues to be defined. The objective of this analysi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gale, Sara, Trinh, Huong, Tuckwell, Katie, Collinson, Neil, Stone, John H., Sarsour, Khaled, Pei, Jinglan, Best, Jennie, Birchwood, Christine, Mohan, Shalini V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393272/ https://www.ncbi.nlm.nih.gov/pubmed/30707391 http://dx.doi.org/10.1007/s40744-019-0139-5

Ejemplares similares

Risk Associated with Cumulative Oral Glucocorticoid Use in Patients with Giant Cell Arteritis in Real-World Databases from the USA and UK
por: Gale, Sara, et al.
Publicado: (2018)

Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial
por: Strand, Vibeke, et al.
Publicado: (2019)

Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations
por: Unizony, Sebastian, et al.
Publicado: (2021)

Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials
por: Strand, Vibeke, et al.
Publicado: (2017)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab
por: Stone, John H., et al.
Publicado: (2019)

Comment on: Benchmarking tocilizumab use for giant cell arteritis
por: Janagan, Shalini, et al.
Publicado: (2022)

Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis
por: Matza, Mark A, et al.
Publicado: (2023)

Design of the Tocilizumab in Giant Cell Arteritis Trial
por: Unizony, Sebastian H., et al.
Publicado: (2013)

Benchmarking tocilizumab use for giant cell arteritis
por: Conway, Richard, et al.
Publicado: (2022)

Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population
por: Gale, Sara L., et al.
Publicado: (2019)

Profile of tocilizumab and its potential in the treatment of giant cell arteritis
por: Mollan, Susan Patricia, et al.
Publicado: (2018)

Vision loss in patients with giant cell arteritis treated with tocilizumab
por: Amsler, Jennifer, et al.
Publicado: (2021)

Giant Cell Arteritis With Chronic Bronchitis Successfully Treated With Tocilizumab
por: Ohta, Ryuichi, et al.
Publicado: (2023)

Association of biological antirheumatic therapy with risk for type 2 diabetes: a retrospective cohort study in incident rheumatoid arthritis
por: Paul, Sanjoy K, et al.
Publicado: (2021)

Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
por: Best, Jennie H., et al.
Publicado: (2020)

Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis
por: Seitz, Luca, et al.
Publicado: (2021)

Tocilizumab for relapsing and remitting giant cell arteritis: a case series
por: Saha, Pratyasha, et al.
Publicado: (2022)

Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study
por: Kim, Seoyoung C., et al.
Publicado: (2017)

Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis
por: Samson, Maxime, et al.
Publicado: (2021)

Is Tocilizumab Effective and Safe in Polymyalgia Rheumatica and Giant-Cell Arteritis With Polymyalgia Rheumatica?
por: Farinango, Michelle, et al.
Publicado: (2022)

Estimating the Cost of Illness of Giant Cell Arteritis in the United States
por: Babigumira, Joseph B., et al.
Publicado: (2017)

Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis
por: Evans, Jobie, et al.
Publicado: (2016)

55. A case for continuing tocilizumab beyond 12 months in giant cell arteritis?
por: Ming, Caroline, et al.
Publicado: (2019)

Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
por: Butryn, Michaela, et al.
Publicado: (2021)

Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients
por: Loricera, Javier, et al.
Publicado: (2022)

The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis
por: Conticini, Edoardo, et al.
Publicado: (2020)

Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis
por: de Boysson, Hubert, et al.
Publicado: (2021)

Atypical Cogan's Syndrome Mimicking Giant Cell Arteritis Successfully Treated with Early Administration of Tocilizumab
por: Hara, Kazusato, et al.
Publicado: (2021)

Tongue necrosis secondary to giant cell arteritis, successfully treated with tocilizumab: a case report
por: Cho, Young Min, et al.
Publicado: (2023)

Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
por: Best, Jennie H, et al.
Publicado: (2019)

Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis
por: Gabay, Cem, et al.
Publicado: (2016)

Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources
por: Monemi, Sharareh, et al.
Publicado: (2016)

Tocilizumab for faster and safer remission of Takayasu’s arteritis
por: Liao, Hua, et al.
Publicado: (2022)

Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients
por: Regola, Francesca, et al.
Publicado: (2020)

Stevens Johnson Syndrome in a Patient with Giant Cell Arteritis During Short Term Tocilizumab Therapy
por: Venkateswaran, Niranjani, et al.
Publicado: (2020)

Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2021)

Predicting Remission Among Patients With Rheumatoid Arthritis Starting Tocilizumab Monotherapy: Model Derivation and Remission Score Development
por: Collins, Jamie E., et al.
Publicado: (2020)

Giant cell arteritis: immune and vascular aging as disease risk factors
por: Mohan, Shalini V, et al.
Publicado: (2011)

Treatment failure in giant cell arteritis
por: Unizony, Sebastian H, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tdjvtb0peno5mqch8jlchkk7n8